Luc Slegers to hand over responsibility for STADA Europe after 26 years
- Press Release
CEO Albrecht: “We can build on an outstanding foundation”
Bad Vilbel, October 27, 2017 –
After 26 years of service, Luc Slegers is ending his career at STADA Arzneimittel AG and beginning his well-deserved retirement. “This decision was anything but easy for me. My heart said ‘keep going’. My head, on the other hand, led me to the conclusion that now would be the ideal time to hand over responsibility for STADA Europe”, explained the 64-year old native of Belgium. “With the new majority owners Cinven and Bain Capital as well as the new CEO Dr. Claudio Albrecht, STADA is very well-positioned. I see tremendous opportunities for growth in segments where we were previously limited due to the financial resources”, said Slegers optimistically.
“With the departure of Luc Slegers, a manager is leaving us who STADA Arzneimittel AG owes a great debt of thanks”, said the Chairman of the Executive Board at STADA, Dr. Claudio Albrecht. “Luc leaves behind a foundation that we can use to build STADA into an even more important and bigger player in the generics and OTC businesses. He did excellent work. We wish him all the best for his future.”
The father of three girls began his career at STADA in 1991. “We bought a small existing unit by the name of Eurogenerics – today the largest pharmaceutical company in Belgium.” In 1996, Luc Slegers moved to Paris, where he once again started from scratch and built up the French business. Italy followed in 1998 and in further episodes Spain, Portugal and the United Kingdom with the purchase of Britannia and Thornton & Ross. Slegers was considered as Mister Europe at STADA, someone who, together with his colleagues in the individual countries, successfully managed the entire European business – with the sole exception of Germany. “After all those years spending a lot of time in airplanes and living out of a suitcase, I am now looking forward to a somewhat quieter time with my family. I probably won’t be completely withdrawing from business life, because I still have a lot of energy”, said Slegers.
Executive Vice President Generics
About STADA Arzneimittel AG
STADA Arzneimittel AG is a publicly-listed company with headquarters in Bad Vilbel, Germany. STADA consistently focuses on a multi-pillar strategy of generics and branded products (OTC) with an increasingly international market orientation. Worldwide, STADA is represented in more than 30 countries with more than 50 subsidiaries. Branded products such as Grippostad and Ladival are among the highest selling in their product categories in Germany. In financial year 2016, STADA achieved adjusted Group sales of Euro 2,167.2 million, adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of Euro 398 million and adjusted net income of Euro 177.3 million. As of December 31, 2016, STADA employed 10,900 people worldwide.
Additional information for journalists:
STADA Arzneimittel AG / Media Relations / Stadastraße 2–18 / 61118 Bad Vilbel – Germany /
Phone: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / E-Mail: firstname.lastname@example.org